These results indicate that ATP1B1 expression could be used for risk stratification, not only with respect to the entire CN-AML patient population, but also within ELN intermediated-I categories, which could facilitate design of more suitable therapies and has important clinical significance. The gene discussed is ATP1B1; the disease is acute myeloid leukemia.